BioDelivery Sciences Announces Taiwan Regulatory Approval of ONSOLIS

BioDelivery Sciences International, Inc.

announced the regulatory approval of ONSOLIS in Taiwan for the management of breakthrough cancer pain in opioid tolerant, adult patients with cancer.  In Taiwan, BDSI has licensed the commercialization rights to TTY Biopharm, where the product will be marketed under the brand name PAINKYL.  TTY will be responsible for the cost of future product commercialization in Taiwan and expects to launch PAINKYL following receipt of reimbursement pricing from the Taiwanese national healthcare system.  The approval in Taiwan results in a milestone payment of $300,000 to BDSI.  Upon launch, BDSI will receive a royalty on net sales.